Klaus W. Wagner - 19 Aug 2024 Form 4 Insider Report for Boundless Bio, Inc. (BOLD)

Role: Chief Medical Officer
Signature: /s/ Jessica Oien, Attorney-in-Fact for Klaus Wagner, M.D., Ph.D.
Issuer symbol: BOLD
Transactions as of: 19 Aug 2024
Net transactions value: $0
Form type: 4
Filing time: 20 Aug 2024, 19:06:01 UTC
Previous filing: 27 Mar 2024
SEC: View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	BOLD	Stock Option	Disposed to Issuer		-102,564	-100%		0	19 Aug 2024	Common Stock	102,564	$4.10	Direct	F1, F2
transaction	BOLD	Stock Option	Disposed to Issuer		-9,635	-100%		0	19 Aug 2024	Common Stock	9,635	$4.10	Direct	F2, F3
transaction	BOLD	Stock Option	Disposed to Issuer		-94,871	-100%		0	19 Aug 2024	Common Stock	94,871	$4.10	Direct	F2, F4
transaction	BOLD	Stock Option	Disposed to Issuer		-68,080	-100%		0	19 Aug 2024	Common Stock	68,080	$8.19	Direct	F2, F5
transaction	BOLD	Stock Option	Disposed to Issuer		-41,745	-100%		0	19 Aug 2024	Common Stock	41,745	$16.00	Direct	F2, F6
transaction	BOLD	Stock Option	Award		+102,564			102,564	19 Aug 2024	Common Stock	102,564	$3.56	Direct	F1, F2, F7
transaction	BOLD	Stock Option	Award		+9,635			9,635	19 Aug 2024	Common Stock	9,635	$3.56	Direct	F2, F3, F7
transaction	BOLD	Stock Option	Award		+94,871			94,871	19 Aug 2024	Common Stock	94,871	$3.56	Direct	F2, F4, F7
transaction	BOLD	Stock Option	Award		+68,080			68,080	19 Aug 2024	Common Stock	68,080	$3.56	Direct	F2, F5, F7
transaction	BOLD	Stock Option	Award		+41,745			41,745	19 Aug 2024	Common Stock	41,745	$3.56	Direct	F2, F6, F7

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The stock option vested as to 25% of the underlying shares on February 22, 2023, and vests as to the remaining underlying shares in 36 substantially equal monthly installments thereafter.
F2	On August 19, 2024, the Issuer repriced the option. Except as further described in footnote 7, all other terms of the option remain unchanged.
F3	The stock option vests in 48 substantially equal monthly installments beginning on January 13, 2023.
F4	The stock option vests in 48 substantially equal monthly installments beginning on July 13, 2023.
F5	The stock option vests in 48 substantially equal monthly installments beginning on March 15, 2024.
F6	The stock option vests in 48 substantially equal monthly installments beginning on April 27, 2024.
F7	The exercise price of the option is $3.56 per share, representing the fair market value per share of the common stock on the date of the repricing; provided that the exercise price will be increased to the original exercise price before repricing if, prior to the "premium end date" (as defined below), the repriced option is exercised or the reporting person's employment is terminated for any reason other than a "qualifying termination" (as defined below). The "premium end date" means the earliest of: (i) August 19, 2026, (ii) the date immediately prior to the closing of a change in control, or (iii) the date of the employee's qualifying termination. A "qualifying termination" means (a) the involuntary termination of the employee's employment by the Company due to a reduction in force (and other than for cause), or (b) the employee's termination due to death or disability.